Organotypic slice cultures of human gastric and esophagogastric junction cancer

Cancer Medicine

Volumn 5, Issue 7, 2016, Pages 1444-1453

  Koerfer, Justus ^a,b   Kallendrusch, Sonja ^a   Merz, Felicitas ^a   Wittekind, Christian ^a   Kubick, Christoph ^a   Kassahun, Woubet T ^a   Schumacher, Guido ^c   Moebius, Christian ^c   Gaßler, Nikolaus ^c   Schopow, Nikolas ^a   Geister, Daniela ^d   Wiechmann, Volker ^d   Weimann, Arved ^d   Eckmann, Christian ^e   Aigner, Achim ^a   Bechmann, Ingo ^a   Lordick, Florian ^b  

^a Universities of Leipzig   (Germany)

^b University Cancer Center Leipzig (UCCL)   (Germany)

^c KLINIKUM BRAUNSCHWEIG   (Germany)

^d Klinikum St Georg   (Germany)

^e Klinikum Peine   (Germany)

Author keywords

Chemosensitivity; esophagogastric junction cancer; gastric cancer; organotypic slice cultures; personalized treatment

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; CISPLATIN; CYTOKERATIN 8; CYTOKERATIN AE1; CYTOKERATIN AE3; FLUOROURACIL; KI 67 ANTIGEN;

ADJUVANT THERAPY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER TISSUE; CELL PROLIFERATION; CHEMOSENSITIVITY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG MECHANISM; ESOPHAGUS CANCER; EX VIVO STUDY; GASTROESOPHAGEAL JUNCTION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; PREDICTION; PRIORITY JOURNAL; PROTEIN CLEAVAGE; STOMACH CANCER; TISSUE CULTURE TECHNIQUE; TISSUE PREPARATION; TISSUE SLICE; TISSUE STRUCTURE; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT;

EID: 85006181436     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.720     Document Type: Article

References (23)

1. Lordick, F., S. Lorenzen, Y. Yamada, and D. Ilson. 2014. Optimal chemotherapy for advanced gastric cancer: is there a global consensus? Gastric Cancer Off. J. Int. Gastric Cancer Assoc. Jpn. Gastric Cancer Assoc. 17:213–225.
2. Cunningham, D., W. H. Allum, S. P. Stenning, J. N. Thompson, C. J. H. Van de Velde, M. Nicolson, et al. 2006. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N. Engl. J. Med. 355:11–20.
3. Ychou, M., V. Boige, J.-P. Pignon, T. Conroy, O. Bouché, G. Lebreton, et al. 2011. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 29:1715–1721.
4. Van Hagen, P., M. C. C. M. Hulshof, J. J. B. van Lanschot, E. W. Steyerberg, M. I. van Berge Henegouwen, B. P. L. Wijnhoven, et al. 2012. Preoperative chemoradiotherapy for esophageal or junctional cancer. N. Engl. J. Med. 366:2074–2084.
5. Smalley, S. R., J. K. Benedetti, D. G. Haller, S. A. Hundahl, N. C. Estes, J. A. Ajani, et al. 2012. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 30:2327–2333.
6. Sasako, M., S. Sakuramoto, H. Katai, T. Kinoshita, H. Furukawa, T. Yamaguchi, et al. 2011. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 29:4387–4393.
7. Bang, Y.-J., Y.-W. Kim, H.-K. Yang, H. C. Chung, Y.-K. Park, K. H. Lee, et al. 2012. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet 379:315–321.
8. Moehler, M., C. T. H. Baltin, M. Ebert, W. Fischbach, I. Gockel, L. Grenacher, et al. 2015. International comparison of the German evidence-based S3-guidelines on the diagnosis and multimodal treatment of early and locally advanced gastric cancer, including adenocarcinoma of the lower esophagus. Gastric Cancer. 18:550–563.
9. Schmidt, T., L. Sicic, S. Blank, K. Becker, W. Weichert, T. Bruckner, et al. 2014. Prognostic value of histopathological regression in 850 neoadjuvantly treated oesophagogastric adenocarcinomas. Br. J. Cancer 110:1712–1720.
10. Blank, S., F. Lordick, F. Bader, M. Burian, M. Dobritz, L. Grenacher, et al. 2015. Post-therapeutic response evaluation by a combination of endoscopy and CT scan in esophagogastric adenocarcinoma after chemotherapy: better than its reputation. Gastric Cancer 18:314–325.
11. Lowy, A. M., P. F. Mansfield, S. D. Leach, R. Pazdur, P. Dumas, and J. A. Ajani. 1999. Response to neoadjuvant chemotherapy best predicts survival after curative resection of gastric cancer. Ann. Surg. 229:303–308.
12. Mansour, J. C., L. Tang, M. Shah, D. Bentrem, D. S. Klimstra, M. Gonen, et al. 2007. Does graded histologic response after neoadjuvant chemotherapy predict survival for completely resected gastric cancer? Ann. Surg. Oncol. 14:3412–3418.
13. Kelsen, D. P., K. A. Winter, L. L. Gunderson, J. Mortimer, N. C. Estes, D. G. Haller, et al. 2007. Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 25:3719–3725.
14. Lordick, F., K. Ott, B.-J. Krause, W. A. Weber, K. Becker, H. J. Stein, et al. 2007. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol 8:797–805.
15. Sasako, M., M. Terashima, W. Ichikawa, A. Ochiai, K. Kitada, I. Kurahashi, et al. 2015. Impact of the expression of thymidylate synthase and dihydropyrimidine dehydrogenase genes on survival in stage II/III gastric cancer. Gastric Cancer. 18:538–548.
16. Merz, F., F. Gaunitz, F. Dehghani, C. Renner, J. Meixensberger, A. Gutenberg, et al. 2013. Organotypic slice cultures of human glioblastoma reveal different susceptibilities to treatments. Neuro-Oncol. 15:670–681.
17. Gerlach, M. M., F. Merz, G. Wichmann, C. Kubick, C. Wittekind, F. Lordick, et al. 2013. Slice cultures from head and neck squamous cell carcinoma: a novel test system for drug susceptibility and mechanisms of resistance. Br. J. Cancer 110:479–488.
18. Vaira, V., G. Fedele, S. Pyne, E. Fasoli, G. Zadra, D. Bailey, et al. 2010. Preclinical model of organotypic culture for pharmacodynamic profiling of human tumors. Proc. Natl. Acad. Sci. USA 107:8352–8356.
19. Holliday, D. L., M. A. Moss, S. Pollock, S. Lane, A. M. Shaaban, R. Millican-Slater, et al. 2013. The practicalities of using tissue slices as preclinical organotypic breast cancer models. J. Clin. Pathol. 66:253–255.
20. Lordick, F., W. Allum, F. Carneiro, E. Mitry, J. Tabernero, P. Tan, et al. 2014. Unmet needs and challenges in gastric cancer: the way forward. Cancer Treat. Rev. 40:692–700.
21. Miao, R.-L. 2014. Towards personalized perioperative treatment for advanced gastric cancer. World J. Gastroenterol. 20:11586.
22. Hughes, P., D. Marshall, Y. Reid, H. Parkes, and C. Gelber. The costs of using unauthenticated, over-passaged cell lines: how much more data do we need? 2007. Biotechniques. 43:575, 577–578, 581–582 passim.
23. Kamb, A. 2005. What's wrong with our cancer models? Nat. Rev. Drug Discov. 4:161–165.